Top in endocrinology: Menopausal hormone therapy; bone turnover markers and mortality risk
Click Here to Manage Email Alerts
The North American Menopause Society released an updated position statement confirming that the benefits of menopausal hormone therapy outweigh the risks for most women.
In the statement, the advisory panel also discussed the importance of personalized treatment, stressing an individual’s unique benefit-risk profile. It was the top story in endocrinology last week.
Another top story was about a study that found older men with higher concentrations of bone turnover markers, including undercarboxylated osteocalcin, procollagen type 1 N-propeptide and collagen type 1 C-terminal cross-linked telopeptide, are at a higher risk for all-cause mortality.
Read these and more top stories in endocrinology below:
Updated position statement confirms menopausal HT benefits outweigh risks for most women
Menopausal hormone therapy remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause, according to an updated position statement from the North American Menopause Society. Read more.
High levels of bone turnover markers increase risk for all-cause mortality in older men
Older men with higher concentrations of three bone turnover markers have a higher risk for all-cause mortality than those with lower concentrations, according to study findings published in the Journal of Bone and Mineral Research. Read more.
FDA lifts clinical hold on trial for novel stem cell-derived therapy for type 1 diabetes
The FDA has lifted a clinical hold placed on a trial for an investigational stem cell-derived therapy for people with type 1 diabetes, according to an industry press release. Read more.
Worse cardiometabolic health, suboptimal social determinants increase severe COVID-19 odds
Adults with a higher cardiometabolic disease staging score who also experience suboptimal social determinants of health have increased risks for severe COVID-19 outcomes, according to study findings published in Obesity. Read more.
Most adults with thyroid cancer on levothyroxine do not reach target TSH levels
Most patients with differentiated thyroid cancer on levothyroxine suppression therapy do not have a thyroid-stimulating hormone level within the target range, according to study data published in Clinical Endocrinology. Read more.